Answers are grounded in this paper and cite their sources.
Lu to single tumor cells and cell clusters. This may open new horizons for the use of TRT in adjuvant or neoadjuvant settings, or for targeting minimal residual disease.
No takes yet. Share an insight, caveat, or question.
Hindié et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: